scholarly journals Giant locally advanced and metastatic squamous cell skin carcinoma of head and neck region: case report

2020 ◽  
Vol 25 (1) ◽  
pp. 20-22
Author(s):  
Jan Stuk ◽  
Jaroslav Vanasek ◽  
Karel Odrazka ◽  
Martin Dolezel ◽  
Iveta Kolarova ◽  
...  
Keyword(s):  
Case Report ◽  
Head And Neck ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Neck Region ◽  
Skin Carcinoma ◽  
Head And Neck Region ◽  
Squamous Cell Skin Carcinoma

Nimotuzumab with concurrent chemoradiotherapy in patients with locally advanced head and neck cancer (LASCCHN).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6084-6084 ◽  
Author(s):  
Naresh Somani ◽  
Karandikar SM ◽  
Kamlesh Bokil ◽  
Kumar Tapash Bhowmik ◽  
Shyam Agarwal
Keyword(s):  
Monoclonal Antibody ◽  
Adverse Event ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Neck Region ◽  
Open Label ◽  
Term Survival ◽  
Head And Neck Region

6084 Background: Nimotuzumab is a humanized monoclonal antibody targeting EGFR receptors. Unlike other anti-EGFR monoclonal antibodies, it has demonstrated to be safe and effective when combined with chemotherapy or/and radiotherapy. We evaluated safety and efficacy of concurrently administrating nimotuzumab with chemo-radiotherapy in patients with locally advanced inoperable squamous cell carcinomas of head and neck region in a usual health care setting. Methods: Open-label single-arm study. Patients of age 18 years and above with histologically confirmed squamous cell cancer of head and neck region in an inoperable stage (stage III & IV) having an ECOG ≤ 2 were included in the study. Informed consent was obtained from all the patients. The patient were administered injection cisplatin (30 mg/m2 IV) and nimotuzumab (200 mg IV) weekly for six weeks along with radiotherapy of 6600cGy over 33 fractions. Patients were evaluated based on RECIST criteria 24 weeks after the last cycle of chemotherapy. Results: Fifty seven patients were enrolled in the study. Mean age of the patients was 51yr (29 yr-79 yr). Most common site of cancer was oral cavity 32 (56.14%). Fourty six (80.70%) patients completed 6 cycles of therapy. ORR was 80.7%, 34 with CR (59.6%), 12 with PR (21%), 8 with SD (14%), 3 with PD (5.2%). Most common adverse event seen was mucositis (33%) but there was no grade III or IV adverse event. Conclusions: Addition of anti-EGFR monoclonal antibody (nimotuzumab) is safe and efficacious based on the loco-regional response and confirms the available phase II data. The long-term survival benefits based on this encouraging response rate needs to be further evaluated especially in patients with inoperable LASCCN.

Hypopharyngeal Squamous Cell Carcinoma and Laryngeal Neuroendocrine Carcinoma Colliding in the Aryepiglottic Fold: A Case Report

2017 ◽  
Vol 103 (1_suppl) ◽  
pp. S1-S4 ◽  
Author(s):  
Roberta Marangoni ◽  
Simone Mauramati ◽  
Giulia Bertino ◽  
Antonio Occhini ◽  
Marco Benazzo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Neck Region ◽  
Collision Tumor ◽  
Small Cell ◽  
Head And Neck Region

Purpose A collision tumor consists of 2 different histologically distinct and topographically independent tumors merging in the same mass. In the head and neck region they are rare, with only 4 cases reported in the larynx. Case report A 60-year-old heavy smoker complained of a left submandibular lesion in October 2014. The lesion was excised and showed a poorly differentiated carcinoma, suggestive for adenocarcinoma. After a positron emission tomography-computed tomography scan showed increased metabolic activity in the left laterocervical region and right vocal cord, the patient underwent endoscopic biopsy of the lesion of the left piriform sinus, which was positive for moderately differentiated squamous cell carcinoma (SCC). He was then submitted to circular pharyngolaryngectomy, reconstruction with a radial forearm free flap, and bilateral neck dissection. The histopathologic examination showed an in situ and microinvasive SCC of the left pyriform sinus colliding with a high-grade, non-small-cell neuroendocrine carcinoma of the larynx. Conclusions To our knowledge, this is the first case described of laryngeal collision tumor comprising a neuroendocrine component. The choice of treatment of this kind of lesion is difficult because of the presence of 2 different histologies and of the controversial prognostic correlation of non-small-cell neuroendocrine neoplasms of the head and neck region.

Weekly methotrexate in squamous cell cancers of head and neck

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15539-15539 ◽  
Author(s):  
A. B. Pathak ◽  
H. Kulkarni
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Large Scale ◽  
Symptomatic Relief ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Neck Region ◽  
Response Duration ◽  
Outpatient Basis ◽  
Head And Neck Region

15539 Background: The aim was to evaluate response rates and toxicity of weekly methotrexate in locally advanced or recurrent squamous cell cancers of the head and neck region. Methotrexate, oldest non-platinum drugs active in squamous cell cancer of head and neck, was selected for its cost-effectiveness and ease of administration. Methods: Patients with locally advanced, inoperable or recurrent squamous cancers were selected. Sites included anterior two-third tongue, buccal mucosa, alveolus, base tongue, larynx and maxilla. Methotrexate 1 mg/Kg was given intramuscularly on outpatient basis once a week for 6 to 8 weeks along with hydration. Patients who responded well and became resectable were encouraged to undergo surgery. All patients were followed up in the clinic every monthly. Results: Total 19 patients were entered on the study over a duration of 24 months. 12 out of 19 patients had partial response (63%), 5 had stable disease (26%) and 2 patients had disease progression. Symptomatic relief ranged from 25% to 100%. Maximum response duration was 12 weeks. Treatment naïve patients had rapid response. In 5 patients disease became clearly resectable. Toxicity was grade II-III oral mucositis in patients with previous radiation. Sample size is small for a subset analysis. Conclusions: Weekly methotrexate is a simple, cost-effective regimen for palliation in advanced recurrent squamous cell cancers of head and neck region. It should also be evaluated further in large scale trials and especially in neo-adjuvant setting in locally advanced squamous cell cancers of the head and neck region given its rapidity of response and brief duration of therapy. No significant financial relationships to disclose.

scholarly journals Concomitant cemento-osseous dysplasia and aneurysmal bone cyst of the mandible: a rare case report with literature review

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Han-Gyeol Yeom ◽  
Jung-Hoon Yoon
Keyword(s):  
Case Report ◽  
Head And Neck ◽  
Aneurysmal Bone Cyst ◽  
Cystic Lesion ◽  
Bone Cyst ◽  
Neck Region ◽  
Diagnostic Process ◽  
Simultaneous Occurrence ◽  
Head And Neck Region ◽  
Osseous Dysplasia

Abstract Background Concomitant cemento-osseous dysplasia (COD) and aneurysmal bone cyst (ABC) are rare in the head and neck region. In our search of the English language literature, we found only one case report describing the simultaneous occurrence of COD and ABC in the head and neck region. Here, we report a case of COD associated with ABC. Further, we performed a systematic search of the literature to identify studies on patients with COD associated with nonepithelial lined cysts of the jaws. Case presentation The patient was a 32-year-old woman who was referred from a private dental clinic because of a cystic lesion below the mandibular right first molar. She had no pain or significant systemic disease. After performing panoramic radiography and cone-beam computed tomography, the imaging diagnosis was COD with a cystic lesion, such as ABC or solitary bone cyst. Excisional biopsy was performed, which revealed concomitant COD and ABC. Conclusion This case of ABC associated with COD provides insight for the diagnostic process of radiographically mixed lesions with cystic changes.

Sign in / Sign up

Export Citation Format

Share Document